Zacks Investment Research
25 Mar 2026, 16:16 UTC · 31w ago
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Impact · against what's priced in
Fresenius Medical Care (FMS) shows potential for margin expansion and innovation through its FME25+ program and new CAREsystem, but these catalysts are weighed down by stagnation in treatment volumes and weakness in China. The overall outlook remains neutral as modest bottom-line growth is offset by ongoing regulatory and regional headwinds.
- FMS+0.20
No priced-in read yet
- In context
The FME25+ program's cumulative savings of EUR 804 million and the 5008X CAREsystem rollout provide positive catalysts, though they are tempered by flat treatment volumes and weakness in the Chinese market.
Read from the article alone
Search tags
